278 related articles for article (PubMed ID: 20831455)
1. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB
Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
4. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
Kavanaugh A; Antoni C; Krueger GG; Yan S; Bala M; Dooley LT; Beutler A; Guzzo C; Gladman D
Ann Rheum Dis; 2006 Apr; 65(4):471-7. PubMed ID: 16096330
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
[TBL] [Abstract][Full Text] [Related]
6. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
Guenther L; Han C; Szapary P; Schenkel B; Poulin Y; Bourcier M; Ortonne JP; Sofen HL
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):851-7. PubMed ID: 21521375
[TBL] [Abstract][Full Text] [Related]
7. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
8. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
Shikiar R; Heffernan M; Langley RG; Willian MK; Okun MM; Revicki DA
J Dermatolog Treat; 2007; 18(1):25-31. PubMed ID: 17365264
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis.
Rahman P; Puig L; Gottlieb AB; Kavanaugh A; McInnes IB; Ritchlin C; Li S; Wang Y; Song M; Mendelsohn A; Han C;
Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1812-1822. PubMed ID: 27483458
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
Strand V; Schett G; Hu C; Stevens RM
J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
14. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
17. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Igarashi A; Kato T; Kato M; Song M; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):242-52. PubMed ID: 21955098
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.
Kavanaugh A; McInnes IB; Krueger GG; Gladman D; Beutler A; Gathany T; Mack M; Tandon N; Han C; Mease P
Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1666-73. PubMed ID: 23666608
[TBL] [Abstract][Full Text] [Related]
20. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]